Corrigendum to “Evaluation of Complication Rates after Breast Surgery Using Acellular Dermal Matrix: Median Follow-Up of Three Years”

Table 1

Patient collective with ADM-implementation.

ADM	Product	Number of ADM implants used	Number of treated patients	Median patient age (years)	Median follow-up time (months)
HADM	Epiflex® / DIZG	15	12	46 (36-76)	40 (20-50)
PADM	Strattice® / LifeCell	21	16	56 (44-66)	43 (30-54)
BADM	Tutomesh® / rti surgical	16	13	53 (33-74)	20 (12-31)
total	all ADMs	52	41	52 (33-76)	36 (12-54)

Listing of matrix, name of ADM-product and its fabricant, amount of breast reconstructions (BR)/augmentations with usage of ADMs, number of patients treated with ADMs, median patient age and range in years, and median follow-up time and range in months of the given patient collective, which received a breast reconstruction/augmentation with ADM; HADM: human ADM; PADM: porcine ADM; and BADM: bovine ADM.